Effective expression and immunogenicity analysis of HIV-1 HXB2 subtype Tat protein deleted the cysteine-rich region in E. coli

Chinese Journal of Microbiology and Immunology

Volumn 28, Issue 5, 2008, Pages 405-410

  Chen, Lu ^a   Deng, Song Hua ^b   Cao, Jie ^a   He, Jun ^b   Chen, Qiu Li ^a   Jiang, Shao Hua ^a   Liao, Wen Ting ^a   Pan, Wei ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b NONE

Author keywords

Deletion of cysteine rich region; Human immunodeficiency virus type 1; Tat protein

Indexed keywords

EID: 84863229652     PISSN: 02545101     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Apolloni A, Hooker C W, Mak J, et al. Human immunodeficiency virus type 1 protease regulation of tat activity is essential for efficient reverse transcription and replication. J Virol, 2003, 77(18):9912-9921.
2. Li C J, Friedman D J, Wang C, et al. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science, 1995, 268(5209):429-431.
3. Aoki Y, Tosato G. HIV-1 Tat enhances Kaposi sarcoma associated herpesvirus (KSHV) infectivity. Blood, 2004, 104(3):810-814.
4. 2005, 21(3):133-135.
5. Jeang K T, Xiao H, Rich E A. Multifaceted activities of the HIV-1 transactivator of transcription, Tat. J Biol Chem, 1999, 274(41):28837-28840.
6. Ensoli B, Fiorelli V, Ensoli F, et al. Candidate HIV-1 Tat vaccine development:from basic science to clinical trials. AIDS, 2006, 20(18):2245-2261.
7. Zagury J F, Sill A, Blattner W, et al. Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS:a rationale for the use of Tat toxoid as an HIV-1 vaccine. J Hum Virol, 1998, 1(4):282-292.
8. Belliard G, Hurtrel B, Moreau E, et al. Tat-neutralizing versus Tat-protecting antibodies in rhesus macaques vaccinated with Tat peptides. Vaccine, 2005, 23(11):1399-1407.
9. Girard M P, Osmanov S K, Kieny M P. A review of vaccine research and development:the human immunodeficiency virus (HIV). Vaccine, 2006, 24(19):4062-4081.
10. 2005, 21(1):33-36.
11. Siddappa N B, Venkatramanan M, Venkatesh P, et al. Transactivation and signaling functions of Tat are not correlated: biological and immunological characterization of HIV-1 subtype-C Tat protein. Retrovirology, 2006, 3:53.
12. Moreau E, Belliard G, Partidos C D, et al. Important B-cell epitopes for neutralization of human immunodeficiency virus type 1 Tat in serum samples of humans and different animal species immunized with Tat protein or peptides. J Gen Virol, 2004, 85(Pt 10):2893-2901.
13. Moreau E, Hoebeke J, Zagury D, et al. Generation and characterization of neutralizing human monoclonal antibodies against human immunodeficiency virus type 1 Tat antigen. J Virol, 2004, 78(7):3792-3796.
14. Kruger N J, Walker J M. The protein protocol handbook. New Jersey: Hucan Press Inc, 1966:15-20.
15. 2006, 17(2):142-145.
16. Tikhonov I, Ruckwardt T J, Hatfield G S, et al. Tat-neutralizing antibodies in vaccinated macaques. J Virol, 2003, 77(5):3157-3160.
17. Opi S, Péloponèse J M Jr, Esquieu D, et al. Full-length HIV-1 Tat protein necessary for a vaccine. Vaccine, 2004, 22(23-24):3105-3111.
18. Gringeri A, Santagostino E, Muca-Perja M, et al. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients. J Hum Virol, 1998, 1(4):293-298.
19. Pauza C D, Trivedi P, Wallace M, et al. Vaccination with Tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc Natl Acad Sci USA, 2000, 97(7):3515-3519.
20. Bieniasz P D, Grdina T A, Bogerd H P, et al. Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO J, 1998, 17(23):7056-7065.